Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cancer who have limited treatment options. The company’s primary activity centers on discovering and advancing novel small-molecule and peptide-based drug candidates targeting difficult-to-treat malignancies. Its portfolio includes investigational therapies designed to modulate epigenetic and protein-degradation pathways, aiming to address hematologic cancers and solid tumors where existing treatments are inadequate. Salarius Pharmaceuticals operates today in the context of its combination with Decoy Therapeutics, whose AI- and machine learning–enabled platform is used to design and engineer next-generation peptide-conjugate drug candidates. This platform is applied to areas of high unmet medical need, including respiratory viral diseases and gastrointestinal cancers. Headquartered in Houston, Texas, with related research activities connected to hubs such as Cambridge, Massachusetts and New York, the company participates in the broader oncology and antiviral drug development ecosystem, working alongside academic centers, clinical investigators, and industry partners to move its pipeline through preclinical and early clinical development.